GSC
CTXR icon

Ground Swell Capital’s Citius Pharmaceuticals CTXR Stock Holding History

Ground Swell Capital’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,901
Closed -$36K – 79
2023
Q4 		$36K Buy
+1,901
New +$36.1K 0.13% 42

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Ground Swell Capital's CTXR Position: Q1 2024 in Review

Ground Swell Capital sold out of Citius Pharmaceuticals (CTXR) in Q1 2024, closing a stake of 1,901 shares — an estimated $36K sold.

Ground Swell Capital first reported a position in CTXR in Q4 2023 and held it in 1 quarter. The position peaked at $36K in Q4 2023. 73 funds tracked by Wall St. Rank hold CTXR as of Q1 2024.

  • Ground Swell Capital reported no remaining Citius Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Ground Swell Capital sold 1,901 Citius Pharmaceuticals shares in Q1 2024, an estimated $36K.
  • Ground Swell Capital first reported a position in Citius Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Ground Swell Capital's Citius Pharmaceuticals position peaked at $36K in Q4 2023.
  • 73 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2024.

Based on Ground Swell Capital's 13F filing for Q1 2024, filed 14 May 2024.